PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsCommentHow worried should we be about the 'slippery slope to designer babies'?

BioNews

How worried should we be about the 'slippery slope to designer babies'?

Published 22 July 2013 posted in Comment and appears in BioNews 714

Author

Professor Stephen Wilkinson

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.

Why are potentially positive developments like mitochondrial replacement therapy and next-generation sequencing greeted with talk of 'designer babies', and is such language justified?

Two
recent news stories have provoked talk of 'designer babies': the government's decision to move towards allowing mitochondrial replacement therapy (MRT); and the announcement, at this month's ESHRE
conference
, that the first child has been born
following the use of 'next-generation sequencing' (NGS). Both techniques have therapeutic
goals. MRT aims to enable patients to have children free from mitochondrial disorders, many of which are fatal. NGS aims to increase success rates for IVF.
So why are potentially positive developments like this greeted with talk of 'designer
babies', and is such language justified?

The expression 'designer babies' is rarely
defined with clarity. It evokes thoughts of parents unhealthily obsessed with
their child's appearance or who want to enhance their children to create, as Heather Long puts it, 'a kind of demi-god race
that will be taller, healthier [and] better-looking'. But 'designer babies' is at
the same time applied much more widely to cases that have nothing to do with
enhancement or with the way children look. Given this ambiguity, we should
approach claims about 'designer babies' with considerable caution.

One of the main arguments lying behind
people's concerns about 'designer babies' is the slippery slope. David
King
, talking about MRT, says: 'Once we've
crossed this crucial ethical line, which says that we shouldn't create babies
that have been genetically altered, it becomes very difficult to then stop when
the next step is wanted and then the next step after that and we will
eventually get to this future that everyone wants to avoid of designer babies.'

While Heather Long, reacting to NGS, says: 'It will
likely be a progression from just wanting a child, to wanting one less likely
to get certain diseases, to wanting one more likely to have traits associated
with being taller or more artistic or athletic. From there, it's not too hard
to imagine something akin to the Subway sandwich line where you select
different traits a la carte.'

The
basic idea behind the slippery slope argument is that even if X isn't itself wrong,
we shouldn't accept or allow X because that would be to step onto the 'slippery
slope' to Y — and Y really is wrong. Not all slippery slope arguments are
defective. Some work; some don't. Whether they work depends on two questions. Is
the slope as slippery as is claimed — will X inevitably lead to Y? And is Y as
bad as it's made out to be?

Take
MRT. The slippery slope argument is that anything short of a categorical prohibition
on the genetic modification of human embryos will lead us 'down the slope' to unfettered
modification ('designer babies'). Why? Because, so it's claimed, once the
principle of 'no genetic modification' has been abandoned then we won't have
any basis on which to object to genetic modification of any kind.

This,
however, supposes that there aren't ethical principles that would allow us to
draw a line between MRT and unfettered genetic modification — but there are some
such principles. One is the idea that human genetic modification is permissible
only when its purpose is to prevent illness. This seems plausible to many, such
as those who regard using reproductive biology to avoid disease as good, but
have reservations about its use for some other purposes. And a parallel principle
can be found in existing UK law on embryo selection
and testing
, which is
permitted only for a limited range of purposes, mostly to do with the health of
the resultant child, or with increasing the chances of a live birth. So the possibility
of operating with a principle like this, and of embedding it in law, casts
doubt on this slippery slope argument. (There are of course other possible
responses to this slippery slope argument. For example, it might be suggested
that the distinction between mitochondrial and nucleur DNA is important, or
that MRT is not really an instance of 'modification' in the relevant sense of the word.)

Then
there's the question of just how bad a world containing 'designer babies' would
be. Heather Long's worry seems in large part about NGS's
effects on socio-economic inequality. Inequality is something we should all be
concerned about, but whether it constitutes an objection specifically to MRT or
NGS is far from clear.

First,
concerns about unfair distribution can be raised about most new (and many old)
technologies. Anything which gives the owner/user an advantage and can only be
afforded by the rich can be objected to on this ground — be it smart phones, hospitals,
motorways, refrigeration, or school books. Second, Long's worry about
inequality seems only to apply to human enhancement, rather than 'designer
babies' more widely, for parents who merely choose their children's eye and
hair colours are unlikely to give them much of an advantage, especially in an
age where contact lenses and dyes can achieve similar effects. Third, we can't
just assume that new technologies have negative effects on social inequality. Indeed,
one of the claims made for NGS is that it could make infertility treatment much
cheaper by increasing success rates; it could therefore increase access to IVF
for the less well-off.

How
worried then should we be about the 'slippery slope to designer babies'? As I've
said, we shouldn't automatically reject slippery slope arguments; some of them do
work. But the ones presented so far in relation to MRT and NGS are unconvincing.
This is partly because we need a clearer idea of what exactly a 'designer baby'
is and what would be wrong with creating one; we need to know what's at the
bottom of the 'slope' and why we should be afraid of it. And it's partly
because there's reason to believe, based on other areas of policy and practice,
that we're capable of distinguishing (albeit imperfectly) interventions that
are genuine treatments for patients from those which merely satisfy people's
trivial cosmetic preferences. Provided that we can make such distinctions then
the 'slope' may not be anything like as 'slippery' as is sometimes supposed.

Related Articles

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
Reviews
11 August 2014 • 5 minutes read

Book Review: Truly Human Enhancement - A Philosophical Defence of Limits

by James Storm

Nicholas Agar has endeared himself to the enhancement debate by being a little bit afraid of 'post humans' — the real life supermen who could very well use their powers for evil and enslave the rest of humanity. It may come as no surprise then that Agar's latest venture into the debate continues in much the same vein....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
2 December 2013 • 5 minutes read

Is mitochondrial replacement therapy eugenic and incompatible with human dignity?

by Dr John Appleby and 2 others

A group of European parliamentarians from the Council of Europe recently issued a declaration objecting to the HFEA's policy advice on experimental mitochondrial replacement therapy claiming that MRT is eugenic and inconsistent with human dignity. These are substantial moral claims, ones that deserve closer scrutiny, and it is an interesting and important exercise to consider how successful such arguments are...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
21 October 2013 • 3 minutes read

23 and your sperm donor?

by Dr Ruth Stirton

23andMe describes its Inheritance Calculator as an engaging way for their clients to 'dip their toes into genetics' providing an opportunity to explore the 'fun traits like eye colour and muscle performance'[2] that their offspring might inherit....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 October 2013 • 3 minutes read

23andMe's 'designer baby' tool patent draws attention

by Dr Sophie Pryor

A US genetics company has been awarded a patent that relates to a DNA analysis service that predicts a baby's traits on the basis of its parents' genes....

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
8 July 2013 • 2 minutes read

First baby born from 'cheaper' gene sequencing of IVF embryos

by Siobhan Chan

A 'powerful' form of genome analysis could improve embryo selection for IVF, according to scientists who report that the first baby has been born from this method...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
1 July 2013 • 4 minutes read

UK Government backs mitochondrial replacement

by Dr Rosie Morley

The UK Government is to support the introduction of mitochondrial replacement therapy. The IVF-based procedure could allow women with mitochondrial disease the opportunity to have healthy children, by replacing their own, faulty, mitochondria with healthy mitochondria from a donor....

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
Comment
7 January 2013 • 3 minutes read

Biotechnology, choice and the public good

by Dr Peter Mills

How valuable are emerging biotechnologies? Of all the questions about the prospects of the life sciences, this is the one that UK policy makers seem most eager to answer...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
Comment
31 October 2012 • 4 minutes read

IVF and the prevention of mitochondrial DNA disease: the moral issues

by Professor Alison Murdoch

Medicine has faced many controversial milestones, none more so than those involving reproduction. The UK Government must now decide whether we can use IVF technology to reduce the risk of transmission of mitochondrial DNA abnormalities. Will they accept it or reject it?...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« The inconvenient truth of fertility decline

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Recent
4 July 2022 • 4 minutes read

Widening the debate about direct-to-consumer genetic testing and donor conception

4 July 2022 • 3 minutes read

Join PET and Genomics England to celebrate the 200th birthday of Gregor Mendel

27 June 2022 • 4 minutes read

Thirty years of PET: our 'Fertility, Genomics and Embryo Research' report

27 June 2022 • 5 minutes read

Children's rights and donor conception: What next?

20 June 2022 • 4 minutes read

The problems with lifting donor anonymity earlier

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856